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ABSTRACT
Introduction: HIV drug treatment has greatly
improved life expectancy, but increased risk of
cardiovascular disease remains, potentially due to the
additional burdens of infection, inflammation and
antiretroviral treatment. The Mediterranean Diet has
been shown to reduce cardiovascular risk and mortality
in the general population, but no evidence exists for
this effect in the HIV population. This study will explore
the feasibility of a randomised controlled trial (RCT) to
examine whether a Mediterranean-style diet that
incorporates a portfolio of cholesterol-lowering foods,
reduces cardiovascular risk in people with HIV
dyslipidaemia.
Methods and analysis: 60 adults with stable HIV
infection on antiretroviral treatment and low-density
lipoprotein cholesterol >3 mmol/L will be recruited
from 3 West Midlands HIV services. Participants will
be randomised 1:1 to 1 of 2 dietary interventions, with
stratification by gender and smoking status.
Participants allocated to Diet1 will receive advice to
reduce saturated fat intake, and those to Diet2 on how
to adopt the Mediterranean Portfolio Diet with
additional cholesterol-lowering foods (nuts, stanols,
soya, oats, pulses). Measurements of fasting blood
lipids, body composition and arterial stiffness will be
conducted at baseline, and month 6 and 12 of the
intervention. Food intake will be assessed using the
Mediterranean Diet Score, 3-day food diaries and
metabolomic biomarkers. Questionnaires will be used
to assess quality of life and process evaluation.
Qualitative interviews will explore barriers and
facilitators to making dietary changes, and participant
views on the intervention. Qualitative data will be
analysed using the Framework Method. Feasibility will
be assessed in terms of trial recruitment, retention,
compliance to study visits and the intervention. SD of
outcomes will inform the power calculation of the
definitive RCT.
Ethics: The West Midlands Ethics Committee has
approved this study and informed consent forms. This
trial is the first to test cholesterol-lowering foods in
adults with HIV.
Trial registration number: ISRCTN32090191; Pre-
results.
INTRODUCTION
Highly active antiretroviral therapy (ART) for
the treatment of HIV infection has signiﬁ-
cantly improved life expectancy.1 However,
HIV patients are increasingly experiencing
metabolic complications, such as dyslipidae-
mia and insulin resistance, that increase car-
diovascular disease (CVD), which is now the
commonest cause of death in the optimally
treated HIV population.1 The cluster of dysli-
pidaemia, smoking and poor-quality diets
appears to drive the increased risk of CVD in
the HIV population.2 However, when com-
pared with case-matched controls, people
with HIV infection exhibit a 50% increased
risk of myocardial infarction beyond that
explained by recognised risk factors.3
Therefore, other factors have been proposed
for the excess CVD observed, including the
actions of speciﬁc antiretroviral drugs and the
direct impact of the HIV virus. Speciﬁc ART
drugs have been observed to be associated
with increased risk of myocardial infarction in
a large international cohort;4 this effect is
only partly explained by their effect on
Strengths and limitations of this study
▪ This is a randomised, multicentred, dietary inter-
vention pilot study in adult HIV centres in the UK,
with subjective and objective dietary assessment.
▪ The outcome and process evaluation data will
inform a large definitive trial.
▪ The feasibility study design is not powered to
measure effect size.
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lipids.5 HIV infection per se potentially increases cardio-
vascular (CV) risk via mechanisms involving inﬂamma-
tion,6 7 CD4 cell count depletion,8 altered coagulation,9
dyslipidaemia,10 impaired arterial elasticity11 and endo-
thelial dysfunction.12 In summary, the risk of CVD is ele-
vated in the HIV population via multiple mechanisms.
Dyslipidaemia is a key risk factor for CVD in those
with HIV infection. The current international guidelines
recommend dietary intervention as the ﬁrst-line treat-
ment for HIV dyslipidaemia.13–15 These guidelines are
based on targeting the general population16 17 where
dietary advice, with emphasis on reduction of saturated
fat, has been shown to reduce CVD risk and mortality.18
Presuming that the reduction in CVD risk achieved by
dietary intervention in the general population will be
mirrored in the HIV population is problematic for two
reasons. First, because the precise underlying mechan-
ism of the increased risk of CVD in HIV is unclear19 and
there is a need to consider multiple factors such as
infection, inﬂammation and antiretroviral treatment.
Second, there is debate over the focus on saturated fat
reduction in the absence of consideration of the source
of the saturated fat (vegetable or animal fats) and the
nature of the carbohydrates it displaces.
Given the uncertainties regarding the impact of
dietary interventions on CVD in the HIV population,
this study set out to clarify the potential of the dietary
intervention on modifying low-density lipoprotein chol-
esterol (LDL-cholesterol), a major marker of increased
CVD risk, in the HIV population.
Rationale for intervention
Saturated fat and the National Cholesterol Education
Program
Our meta-analysis of pooled results from four rando-
mised controlled trials (RCTs) demonstrated a clinical
beneﬁt of dietary intervention in reducing triglycerides
by −0.46 mmol/L (95% CI −0.85 to −0.07 mmol/L)
over an average treatment period of 8 months in HIV
patients on antiretroviral therapy, but reported no
effects on LDL-cholesterol or high-density lipoprotein
cholesterol (HDL-cholesterol).20 That review clearly
identiﬁed the need for well-designed, robust trials. One
subsequent trial suggested an improvement in
HDL-cholesterol and highly sensitive C reactive protein
(a marker of CVD risk) as secondary outcomes,
although it was likely underpowered to assess the effects
of lifestyle modiﬁcation on these.21 However, the lack of
effect on LDL-cholesterol may indicate that the interven-
tions used (National Cholesterol Education Program
(NCEP) Therapeutic Lifestyle Changes diet emphasising
reduction in saturated fat to 7% of total calories) are
insufﬁcient to independently alter HIV dyslipidaemia
and associated CV risk.
Mediterranean Diet
The Mediterranean Diet is characterised by: high con-
sumption of olive oil, legumes, unreﬁned cereals, fruits
and vegetables, and moderate consumption of dairy pro-
ducts, ﬁsh and wine, but low consumption of meat. The
Mediterranean Diet has been examined in HIV cohort
studies, with reports of no association between adher-
ence to the Mediterranean Diet and plasma lipid
changes during the ﬁrst year of ART treatment.22
Favourable associations have been reported with insulin
resistance and HDL-cholesterol in patients on ART, but
only in those with fat redistribution, such as visceral fat
accumulation and/or subcutaneous fat wasting.23 One
parallel, randomised trial has been conducted in the
HIV population, comparing low-fat NCEP diet versus the
same with additional Mediterranean components. The
ﬁndings were unfavourable in both arms, with increases
in triglyceride levels in the NCEP group and increases in
cholesterol levels in the modiﬁed Mediterranean group.
It was, however, a pilot study, and variance was not
reported, making interpretation difﬁcult.24
Despite the lack of available evidence in the HIV
population, the strength of the effects of the
Mediterranean Diet documented in the non-HIV popu-
lation cannot be ignored. Its importance is evident from
observational cohort studies,25 a secondary prevention
trial,26 and a primary prevention trial27 demonstrating
substantial reduction in CV morbidity and mortality. In a
Spanish population at high CV risk, but with no disease
present, the Mediterranean Diet reduced the incidence
of major CV events by 30% (HR 0.70, 95% CI 0.55 to
0.89).27 Despite the large beneﬁt seen in clinical end
points, the effect on blood lipids was less dramatic, with
no signiﬁcant difference in LDL-cholesterol between the
Mediterranean Diet and Low Fat Diet groups due to
similar reductions of 0.15 mmol/L. The Mediterranean
Diet appears to beneﬁt HDL-cholesterol, with increased
levels of 0.08 mmol/L (95% CI 0.04 to 0.10) producing
a reduction in total cholesterol to HDL ratio.28 One UK
study has explored the feasibility of implementing the
Mediterranean Diet in a non-Mediterranean setting,
demonstrating that Northern European CVD patients
could adopt and maintain a Mediterranean Diet.29
Functional foods and the Portfolio Diet
American guidelines have recommended the use of
functional foods as additional options to enhance the
effectiveness of cholesterol-lowering diets.
Foods with cholesterol-lowering properties have been
examined in clinical trials in the general population,
demonstrating 6% reductions in LDL-cholesterol with
15 g/day soya protein;30 7–10% reductions with 2 g/day
plant stanols;31 3–5% reductions with 3 g/day β-glucans
in oats;32 and a dose-dependent effect of 1%
LDL-cholesterol reduction with every 4–11 g of nut con-
sumption.33 When these cholesterol-lowering foods
(plant sterols, soy protein, viscous ﬁbre and almonds)
were combined into a ‘Portfolio Diet’, the effect was
magniﬁed, producing an LDL-cholesterol reduction of
−1.36 mmol/L (29%) in short-term feeding trials.34
Reductions of 29% were sustained at 1 year in a
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free-living trial, under real-life conditions, but only for
the one-third of the participants who achieved complete
adherence. The treatment effect was halved to 13%
LDL-cholesterol reduction (−0.61 mmol/L)35 in the
intention-to-treat analysis, but was still impressive. This
ﬁnding was consistent with LDL-cholesterol reductions
of 14% (−0.67 mmol/L) in another free-living trial of
6 months, where adherence to the portfolio components
was only 46%.36
Motivational interviewing
Dietary interventions are a form of behavioural interven-
tion to help improve adoption of behaviour change. The
UK National Institute for Health and Care Excellence
(NICE) guidelines (2007) recommend selecting interven-
tions that motivate and support people to feel positive
about the beneﬁts of health-enhancing behaviours.37
These recommendations apply to motivational interview-
ing, which has been shown to be effective in the domain
of diet and exercise.38 Motivational interviewing was devel-
oped by Miller and Rollnick, and subsequently ascribed to
the transtheoretical model of change.39 Motivational inter-
viewing is based on four key principles: expressing
empathy, developing discrepancy, rolling with resistance
and enhancing self-conﬁdence. Systematic reviews in
obesity management,40 diabetes prevention41 and CV risk
reduction in high-risk groups,42 indicate that such robust
behavioural change strategies are key to effective lifestyle
change programmes. Guidelines for diabetes prevention43
and obesity prevention/management44 recommend indi-
vidual level intervention using established, well-deﬁned
behaviour change techniques (goal setting, relapse pre-
vention, self-monitoring, motivation interviewing, prompt-
ing self-talk, individual tailoring and time management).
In this study, motivational interviewing will facilitate the
development of individualised approaches to support
behaviour change in relation to diet, enhance participant
self-efﬁcacy and motivate participants to change, achieve
their goals and maintain behaviours.
Intervention proposed for this trial
The hypothesis of the current study is to combine the
effect observed in the general population of the CV
event reduction from the Mediterranean Diet with the
cholesterol reduction from the functional foods of the
Portfolio Diet. This dietary advice is to be delivered in
the motivational interviewing style, as advocated by
HEART UK in their Ultimate Cholesterol Lowering Plan
(UCLP), which is also based on the Portfolio Diet.
Therefore, this study aims to examine whether a diet
that is low in saturated fat, and incorporates cholesterol-
lowering foods and a Mediterranean Diet style, reduces
blood lipid levels in patients with stable HIV infection
on antiretroviral treatment.
The study is not designed to determine which of the
food or nutrient components are responsible for the
effect observed, but to assess the combined impact of
the two dietary patterns (low saturated fat and
Mediterranean Portfolio Diet) on LDL-cholesterol. The
reason for investigating dietary patterns rather than
examining isolated nutrients is that they are more rele-
vant to the ways people choose their foods and the possi-
bility of observing the potential additive or synergistic
effects of combining different dietary components.45
A parallel pilot trial design with an active comparator
was selected for two reasons. First to ensure that entering
the study would not disadvantage participants who had
access to dietary advice as part of their current standard
of care. Second, to prevent performance bias resulting
from differential levels of attention between groups, and
the preferred outcomes of the potential participants.
The 2008 Medical Research Council Framework46 was
followed for the development of this complex interven-
tion, including examining the theoretical basis, develop-
ing the intervention with patient input, using patient
focus groups to identify potential barriers to recruit-
ment, and noting preferred outcomes. Based on the evi-
dence from this development process thus far, a pilot
trial is proposed to test the feasibility and acceptability
of procedures for recruitment, allocation, retention and
intervention, to inform the viability of conducting a
deﬁnitive multicentre trial to evaluate the effectiveness
of this speciﬁc dietary intervention in this population.
Study objectives
The aim of this study is to assess the feasibility, and pilot
the design and delivery of a RCT that will subsequently
form the framework for a deﬁnitive RCT to evaluate the
effectiveness of dietary intervention on CV risk of
people with HIV dyslipidaemia. The objectives are:
1. To obtain reliable estimates for recruitment, reten-
tion and study attendance compliance;
2. To explore the appropriateness of the trial proce-
dures, design and duration;
3. To understand how the intervention works in practice
and its acceptability from the participants’ perspective;
4. To quantify levels of adherence to the dietary inter-
vention and identify contextual factors associated
with variation;
5. To conduct process evaluation to assess ﬁdelity and
quality of implementation;
6. To determine estimates of the variability of the
outcome measures and markers of CV risk, anthropo-
metric measures and quality of life, including
LDL-cholesterol, pulse wave velocity and waist
circumference.
METHODS AND ANALYSIS
Design
This is a two-arm, parallel, multicentre RCT for people
with HIV dyslipidaemia. The two arms are:
1. Diet1—reduced saturated fat;
2. Diet2—Mediterranean Portfolio Diet.
Randomisation will be stratiﬁed according to gender
and smoking status. The trial is funded by the National
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Institute for Health Research (NIHR) Doctoral
Fellowship Programme and has been registered with the
International Standard Randomised Controlled Trial
Number registry (identiﬁer: ISRCTN32090191). The
study ﬂow chart in ﬁgure 1 shows progression through
the study for individual participants.
Setting
The study is a multicentre study set in three HIV services
in the West Midlands (Birmingham Heartlands Hospital,
Queen Elizabeth Hospital Birmingham and City of
Coventry Health Centre). The West Midlands represents
10% of the population of England and Wales, and spans
the range of population densities, urbanisation and
socioeconomic proﬁling typical of the UK. It has the
largest ethnic diversity outside of London, with 17.3% of
the population being African, Caribbean or Asian.47
Participants
The target population is adults attending HIV services
within the West Midlands who have been stable on ART
treatment for >6 months, and who have viral suppression
Figure 1 Consort flow diagram
for Best Foods for Your Heart
trial. MDT, multi-disciplinary team;
MUFA, monounsaturated fatty
acids.
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and LDL-cholesterol >3 mmol/L. The inclusion criteria
are: ﬂuency in English and intent to stay in the UK for
1 year. The exclusion criteria are: planning pregnancy in
next 6 months; current use of lipid-lowering agents (any
interfering drug or diet); secondary causes of dyslipidae-
mia (renal or liver disease, diabetes, hypothyroidism,
familial hyperlipidaemia); known nut allergy; unstable psy-
chiatric disorder (including eating disorders); current par-
ticipation in a weight loss programme or other dietary
intervention; and inability to understand printed materi-
als. When in doubt, the opinion and approval of the trial
investigation team will be sought.
Sample size
A CI approach was used to estimate the sample size
required to establish feasibility.48 The criterion for
success is that the deﬁnitive trial will be feasible if the
attrition rate is <20% (or complete follow-up in at least
80% of all recruited participants). With a sample size of
60 participants, the expected attrition rate of 20% can
be estimated with a 20% (95% CI 10% to 30%) margin
of error. This upper bound of 30% is appropriate as it is
the cut-off used to determine which trials constitute best
evidence for behavioural intervention49 and which trials
qualify to receive funding for implementation by the
Centers for Disease Control and Prevention 2010.50
Recruitment
Recruitment will be conducted using a number of
methods: advertising poster in waiting room for patients;
referral from multidisciplinary team providing HIV care;
and screening of patient blood results for LDL-cholesterol
>3 mmol/L. Patients will be assessed for eligibility by the
researcher. Eligible patients will be handed or posted an
invitation letter and participant information sheet contain-
ing details of all the interventions and assessments to be
expected. To avoid contamination, the description of the
dietary interventions will be general and applicable to
both groups. Patients will be given at least 24 h to consider
the information before being contacted to conﬁrm the
date of their next routine blood test appointment, and
reminded to attend in a fasted state, with no food con-
sumed 12 h prior to the appointment time. Written
informed consent will be obtained from all participants at
their ﬁrst trial visit, prior to baseline measurements.
Allocation strategy
Participants will be randomly allocated to Diet1 or Diet2
in a 1:1 ratio on their second trial visit. A statistician
from the University of Birmingham will produce a
computer-generated allocation sequence using random
block sizes of 2 and 4, stratiﬁed by gender and smoking
status. Block sizes will be concealed until completion of
the trial. The research dietitian will allocate participants
according to the diet number concealed in the next
sequentially numbered, opaque, sealed envelope, rele-
vant for their gender and smoking status. As this is a
complex intervention, it is not possible to blind the
participants, nor is it possible to blind the healthcare
professionals. The terms Diet1 and Diet2 will be used
with the aim of achieving participant blinding to the
exact content of the diet and type of foods included, to
prevent internet searching of diet titles and potential
contamination between groups. The success of the level
of blinding achieved will be evaluated using questions
on intervention preference and self-belief in success.
Data to be collected at baseline, month 6 and 12
Sociodemographic data on age, gender, ethnicity and
occupational status will be collected. Biomedical data will
be collected on weight, height, body mass index, waist cir-
cumference, body composition and stool frequency/bowel
habit. Weight and body composition will be measured in
light clothing, barefoot, on a Class 3 Tanita BC420SMA
weighing scale (meets Medical Device Directive and
Non-Automatic Weighing Instruments European regula-
tions) (Tanita, Tokyo, Japan). Participants will be asked to
abstain from food and drink for 4 h prior to the assess-
ment. Height will be measured to 0.1 cm using stadi-
ometers with the supported stretch stature method. Waist
circumference will be measured horizontally at the top of
the iliac crest, with a ﬂexible non-stretching Seca tape, to
0.1 cm. Bowel habit will be assessed via self-report, to ascer-
tain any disturbances that may require ﬁbre and ﬂuid
intake modiﬁcation.
Lifestyle data will be collected on smoking status,
alcohol intake and CV risk factors, to enable calculation
of QRISK 10-year CV risk.51 Blood pressure will be mea-
sured seated, with automated sphygmomanometer
(Omron, The Netherlands), taking the average of three
consecutive readings. Intensity of physical activity will be
measured objectively using the Actigraph GT3X+ accel-
erometer (Actigraph, Florida, USA), a triaxial movement
sensor that also records step counts. It will be worn over
the right hip for 7 days, during waking hours, as this is
the ideal period to obtain consistent measures.52 Mean
counts per minute will be compared between groups, to
identify any potential inﬂuence of physical activity as a
confounding factor. Best practices will be followed with
regard to monitor use protocols, calibration and analysis
of accelerometer data.53
Aortic pulse wave velocity, as a measure of arterial stiff-
ness, is an independent predictor of CV risk and mortal-
ity.54 Aortic pulse wave velocity will be measured from
the right carotid and femoral arteries with the Vicorder
system (Skidmore Medical, UK).55 Duplicate recordings
will be made and saved, once a steady, consistent pattern
of pulse waveforms is achieved and maintained for at
least 10 cardiac cycles.
Blood samples will be collected and stored for later
measurement of apolipoprotein A and B, inﬂammatory
markers (highly sensitive C reactive protein) and insulin
sensitivity (fasting insulin, adiponectin). Vitamin E levels
will be measured to monitor any potential effect of plant
stanols on absorption of fat-soluble vitamins.
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Dietary assessment
A number of different dietary assessment tools will be
used to enable cross-validation of methods and explor-
ation of a variety of different strategies for selective
implementation in future trials. Adherence to a
Mediterranean-style diet will be assessed using a 14-item
tool used in the PREDIMED study.27 56 Fruit and vege-
table intake will be assessed using a two-item question-
naire, previously used in studies on healthy adults from
diverse ethnic backgrounds living in a low-income neigh-
bourhood57 and patients with CVD,58 and validated
against plasma and urine biomarkers. A compliance
score will assess consumption of the functional foods
components of the Mediterranean Portfolio Diet inter-
vention at month 6 and 12.35 Dietary intake will be
assessed using a 3-day food diary, recorded either on
paper or on the mobile phone app MyNetDiary
(MyNetDiary Inc, New Jersey, USA). Kitchen scales will
be provided to assess food quantities. The researcher will
review the diaries with participants to clarify brands,
methods of food preparation and recall of missing
foods.59 Where weights of foods are unknown, they will
be estimated using information from Ministry of
Agriculture, Fisheries and Food Portion Sizes.60
Nutritional analysis will be conducted using DietPlan7
dietary analysis software (Forestﬁeld Software Limited,
Horsham). Metabolomic biomarkers will be used to
independently assess dietary compliance, including
trimethylamine-N-oxide and 1-methylhistidine for oily
ﬁsh, urolithin A glucuronide for nut intake, equol for soy
isoﬂavone, and linoleate, oleate and palmitate for olive
oil intake. Urine sample from 24 h collection at baseline
and month 6 will be stored for later metabolic proﬁling
analysis by mass spectrometry using an analytical plat-
form based on 1H proton nuclear magnetic resonance
spectroscopy and mass spectroscopy, at Imperial College
London.61 The quantiﬁed metabolite concentrations will
be individually and collectively regressed against biomet-
ric data and against the global metabolic proﬁles.
Process Evaluation
Process Evaluation questionnaires will be used at baseline
and month 6. Various approaches were selected and com-
bined in the questionnaires to incorporate the compo-
nents recommended by the Medical Research Council
guidelines.46 Fidelity and quality of implementation of the
intervention will be assessed using open-response
questions, to get a general overview of acceptability, as pre-
viously demonstrated in the WATCH IT evaluation,62 and
speciﬁc Likert-ranked questions, to examine participant
perceptions of the strengths and weaknesses of the pro-
gramme, as used in the SHED-ITevaluation.63 Assessment
of diet intrusiveness, the participants’ intention to make
changes and self-belief in success, will be used to support
clariﬁcation of causal mechanisms. Contextual factors asso-
ciated with variation in outcomes will be identiﬁed via a
validated measure of self-efﬁcacy for fat intake behaviour,
containing three task-speciﬁc domains of self-efﬁcacy
(negative mood, positive mood and food availability),
which have been shown to predict different types of fat
reduction behaviours in low-income populations, with var-
iations according to race.64 In trials, such as this one,
where blinding is not possible, the patient’s preference for
treatment can inﬂuence the outcome, especially where
the participant is not simply a passive recipient of the inter-
vention, but is required to engage and make lifestyle
changes. Therefore, intervention group preferences will
be elicited before each randomisation, and used subse-
quently in the analysis of covariance (ANCOVA) to investi-
gate the inﬂuence on LDL-cholesterol of participants’
preferences at baseline.65
Quality of life
One generic (EQ-5D) and one HIV-speciﬁc (MOS-HIV
35-item instrument) will be used to assess the impact of
the trial on the participant’s quality of life. These tools
are deemed the most appropriate adjunct and
HIV-targeted measures for use in HIV clinical trials.66 As
responses to the EQ-5D thermometer tend to reﬂect
physical more than mental health, the Warwick-
Edinburgh Mental Well-being Scale (WEMWBS) will be
used to measure mental well-being. The WEMWBS, a
14-item scale covering subjective well-being and psycho-
logical functioning, has been validated in the UK adult
population.67 Permission has been granted to use these
questionnaires in this study.
Interviews
Qualitative data will be collected from a sample of parti-
cipants at the end of the 6-month intervention period.
Participants will be purposively selected from the Diet2
arm to include men and women of different ethnicities,
with high and low levels of adherence, to reﬂect the
diversity and breadth of experiences of a wide range of
participants. Semistructured interviews will be con-
ducted using open-ended, non-directive questions. The
aim will be to understand participants’ experience of
implementing dietary changes by enabling them to ‘tell
their story’—what they did and how—as well as identify-
ing barriers to, and enablers of, success in making and
maintaining diet changes. It is anticipated that there will
be variations in the effectiveness of the dietary interven-
tion for different individuals in different sociocultural
settings. Analysis of the interview data will serve to
describe and potentially explain these differences and
the factors involved. By exploring participant views on
the intervention, study design and delivery, the inter-
views will identify problems at the feasibility stage to
prevent them occurring at the full trial stage.
Written informed consent for digital recording of the
30–60 min interview will be sought prior to booking a
mutually agreed time and place, enabling the interview
to be conducted either in participants’ homes or a clinic
room with privacy. Participants will be encouraged to
invite their partner, family member or other cohabitant
6 Stradling C, et al. BMJ Open 2016;6:e010821. doi:10.1136/bmjopen-2015-010821
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to join in the interview and give their perspective on
how dietary changes are lived.
The sample size will be around 10 although the actual
number recruited will be determined at the point at
which the researcher is satisﬁed that a good understand-
ing of the barriers and facilitators to making dietary
changes has been achieved.
Interviews will be transcribed verbatim. Data analysis
will be conducted following the Framework Method:
familiarisation, identifying a thematic framework, index-
ing, charting, mapping and interpretation.68 69 Data ana-
lysis and management will be supported by NVivo10
software (QSR International). A subset of interviews will
be independently coded to verify interpretation. Where
possible, data triangulation with cohabitants will be used
to enhance plausibility, trustworthiness and transferabil-
ity of the data analysis process. Reﬂective notes will be
taken in a ﬁeld note diary immediately after each inter-
view and throughout data analysis, to maintain reﬂexivity
of the researcher.
Intervention design
All participants, in both groups, will be invited to attend
three individual consultations with the research diet-
itian, and will receive further telephone reinforcement
and support during the 6-month intervention period.
Appointment times will be offered between 08:00 and
19:00, enabling ﬂexibility for participants who are
working. This will be followed by a 6-month mainten-
ance period, with routine clinic visits only. The same
research dietitian, experienced in HIV nutritional care,
will provide all consultations.
Diet1: low saturated fat
Consultations will focus on reduction of saturated fat to
<10% of energy intake, in line with UK guidelines15 16
and evidence on reducing the risk of CV events.70
Resources will be provided, such as written information,
recipes and online videos, covering various topics includ-
ing sources of saturated fat, food swaps, food labelling,
cooking methods, cheese facts and margarine types.
On completion of the 12-month outcome measure-
ments, participants in group 1 will receive the dietary
information from Diet2 (Mediterranean Portfolio).
Should they choose to adopt the diet, they will be given
the option of having their fasting measurements repeated
at month 18, at their routine blood test appointment.
Diet2: Mediterranean Portfolio
In addition to the information provided to group one,
participants allocated to Diet2 will receive advice and
support to adopt the Mediterranean Diet supplemented
by additional functional foods with cholesterol-lowering
properties. This will be embedded within a motivational
interviewing style consultation to include assessing readi-
ness to change, utilising decisional balance, reﬂective lis-
tening and open-ended questions, to identify needs,
motivators and barriers to changing their diet, helping
the participant to develop and verbalise arguments for
change (desire, ability, reason need and commitment),
and diminish resistance to it. The aim is to help
empower and motivate the patient to make the changes
identiﬁed during goal setting for their speciﬁc change
plan. The dietitian will use the food diary to guide the
participant towards the dietary changes most pertinent
to their current intake while considering socioeconomic
factors and family dynamics. The diet is not prescriptive,
as goals will be negotiated individually with each partici-
pant during their ﬁrst session and reviewed at each visit.
On the randomisation visit, daily consumption of 57 g
tree nuts and 2 g plant stanols will be encouraged in the
form of two handfuls of unsalted mixed nuts (almonds,
cashew nuts, peanuts, Brazil nuts, hazelnuts, pecans,
walnuts, pistachios, macadamia nuts) and a 50 mL
cholesterol-lowering drink. At subsequent sessions, parti-
cipants will be encouraged to continue with the nuts
and stanols, while also aiming to eat 15 g/day soy
protein as soya milk, yogurt or dessert, tofu and meat
substitutes, and adopt a Mediterranean-style diet, with
more vegetables and fruit, olive oil, and approximately
15–20 g/day soluble ﬁbre from oats, pearl barley, lentils,
beans and ﬂaxseed. Supplies of the functional foods
(nuts, soy protein, plant stanols, oats and pulses) will be
given to participants to offset the additional cost of
making dietary changes and inconvenience of searching
for unusual items in supermarkets.
It is acknowledged that trials requiring longer term
dietary change face challenges regarding attrition and
adherence to study requirements, therefore some ﬂexi-
bility with dietary requirements will be provided in order
to facilitate positive experiences and encourage commit-
ment to the long term.71 If the participant is unable to
consume the full amount of one component, for
example, due to taste, they will be encouraged to maxi-
mise the contribution of other components.
In keeping with maintaining the integrity of a
complex intervention, this trial will aim to standardise
the function and process of the intervention, not the
components themselves,72 thus allowing context-level
adaptation, for example, use of ethnicity-appropriate
resources. A sample of consultations will be audio
recorded, for subsequent assessment by an HIV clinical
psychologist, to monitor the quality of the motivational
interviewing and ﬁdelity of the intervention.
Outcome measures
The primary outcomes for this study are feasibility and
acceptability of trial procedures for recruitment, reten-
tion, data completion and the intervention. The proto-
col will be considered viable for a deﬁnitive RCT without
modiﬁcation if the following outcomes are met:
1. Recruitment rates of at least 50% of eligible patients;
2. Attrition rate of <20% by 6 months;
3. Compliance rate of 60% to trial.
If these outcomes are not met, the protocol will be
modiﬁed in light of the study’s ﬁndings.
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Recruitment rate will be measured as proportion of
eligible patients who are subsequently enrolled. Methods
of recruitment will be compared: difference between
recruitment rate from systematic methods (screening
results) and ad hoc methods (posters, referral by multi-
disciplinary team). Reasons will be sought for declined
participation. Appropriateness of eligibility criteria and
their practical application for deﬁnitive trial will be
explored.
Attrition rate is deﬁned as both discontinuation and
loss to follow-up of participants at 6 months. Logistic
regression will be conducted to assess whether comple-
tion is associated with age, gender or allocation prefer-
ence. Reasons for discontinuation will be sought from
participants. The target of 20% (with precision of 10%)
is based on the mean attrition rate from ﬁve Portfolio
Diet studies (13%) and systematic review evidence
(18%),20 although attrition has ranged from 25%24 to
42%73 in other HIV diet studies. Acceptability of the
intervention and group allocation will be explored by
questionnaire, and assessed by comparing attrition rates
between the two groups.
Attendance to appointments, collection of supplied
foods and completion of food diaries will be used as
indicators of participation and study compliance.
Statistical analysis plan
Descriptive ﬁndings will be explored regarding numbers
recruited, completing, dropping out and summary
characteristics of each arm at baseline. CI estimation,
not p value, will be used as the appropriate analysis for
pilot studies.74 For all binary outcomes, we will therefore
compute the number and proportion in each arm, and
95% CI.
Exploratory analysis of the treatment effect will be
conducted. Intention-to-treat analyses will be conducted
with participants as originally allocated at randomisation
to avoid bias. Signiﬁcance levels will be set at <0.05 with
two-tailed tests. Effect size for the performance out-
comes will be explored using ANCOVA with adjustment
for baseline value,75 and we will report mean differences
in outcomes between arms with 95% CIs. SD of each
outcome will be estimated, to inform the power calcula-
tion for a deﬁnitive trial.
Further exploratory analysis will be piloted to high-
light any potential modiﬁcations required for the deﬁni-
tive trial. This will include integrating process and
outcome data to maximise the interpretation of
results.76 For example, to address the question of the
relationship between LDL-cholesterol and variation in
adherence levels to the diet, on-treatment analysis will
be used, in which results for participants who adhered
to the diet will be compared with results from those
allocated to the diet (standard intention-to-treat
approach). To address the question regarding differ-
ences in responses to the intervention between sub-
groups of participants, regression analysis will be used
in the deﬁnitive trial (as the power will be insufﬁcient
in the pilot study), with tests for interactions to identify
participants most and least likely to beneﬁt from the
intervention.
Although this trial is not sufﬁciently powered to
compare outcome between intervention arms, estimates of
differences between arms will be compared. In the event
that the effect of the intervention is large (in the region of
0.5 mmol/L or 10% difference in LDL-cholesterol reduc-
tion between groups at 6 months) this study will have sufﬁ-
cient power and it will be important not to miss such large
effect sizes if they exist.
DISSEMINATION
The Trial Steering Committee will provide overall trial
supervision. The main ethical consideration is to ensure
that the risk of harm to participants is minimised and
that they are fully informed of any risks. Lipid lowering
agents are not permitted during the trial. Should an
individual’s LDL-cholesterol rise above >5 mmol/L, this
will be recorded as an adverse event and they will be
withdrawn from the study, with general practitioner
referral for appropriate medication.
The research dietitian, at study visits, will monitor the
condition of the participants during the trial, requesting
evaluation of potential harms by the participants’ HIV
physician during routine clinic visits. All adverse events,
whether considered trial-related or not, will be docu-
mented in the participant’s case report form, and
reported to the Trial Steering Committee and Sponsor.
Participants will be free to withdraw from the study at
any time. If participants withdraw from the intervention,
they will be asked if they would allow data to be col-
lected at routine clinic appointments.
Electronic trial data will be entered into the encrypted
and password protected trial computer, stored on the
secure hospital server and archived for 5 years after
study completion. Paper copies will be held in the
research ofﬁce for purposes of potential data checking,
and shredded 1 year after study completion.
DISCUSSION
This study is timely for several reasons. First, CVD
remains the largest cause of mortality in the UK77 and
will continue to rise in the ageing HIV population.
Second, current guidelines recommend dietary interven-
tion as ﬁrst-line treatment for HIV dyslipidaemia.13–15
These recommendations are based on guidelines for the
general population16 17 where dietary advice, with
emphasis on reduction of saturated fat, has been shown
to reduce CVD risk and mortality.18 Presuming that the
reduction in CVD achieved by dietary intervention in
the general population will be mirrored in the HIV
population is problematic, given the complexity of CVD
among the HIV population and the potential of differ-
ent contributing mechanisms.19 Third, there are no
studies on dietary intervention, of any kind, in the HIV
population in the UK. Also, there are no known studies
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on cholesterol-lowering foods, nor on the Portfolio Diet,
in the HIV population internationally. Components of
this diet have been incorporated into the UCLP
(HEART UK), but have yet to be evaluated in the UK
population. Therefore, ﬁndings from this feasibility
study utilising the Mediterranean Portfolio Diet in the
HIV population could potentially inform the acceptabil-
ity of this diet in the wider population.
As indicated by the lack of effect found with diets low
in saturated fat, further studies with interventions of
greater intensity and sufﬁcient duration are required to
elucidate the full potential of dietary intervention, and
to ascertain whether modifying the known marker of
increased risk (LDL-cholesterol) modiﬁes the risk itself
(CVD). Therefore, this study aims to examine whether a
diet low in saturated fat, which also incorporates func-
tional foods and a Mediterranean style, reduces blood
lipid levels in patients with HIV infection. If this dietary
intervention can signiﬁcantly reduce blood lipid levels,
patients may have the option of reducing their CV risk
without the need for lipid-lowering medications (with
attendant increasing pill and side effects) or switching
antiretroviral drugs (with the potential risk of losing viro-
logical control of HIV). A reduction of 1 mmol/L in
LDL-cholesterol reduces the risk of dying from heart
disease by nearly 20% in the general population,78 but
this has not been ascertained in the HIV population.
Piloting this trial format will be important in deter-
mining any feasibility challenges and will be used to esti-
mate the time, resources and sample size required for a
full-scale RCT to answer these questions.
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